A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis (UPHOLD)

AbbVie

Status: Completed

Conditions: Rheumatoid Arthritis (RA)

Study type: Observational

Funder types: Industry

Identifiers

NCT04497597

P20-095

Details and patient eligibility

About

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the treatment patterns, achievement of treatment targets and maintenance of response.

Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. Adult participants with moderate to severe RA who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 1660 participants will be enrolled this study, worldwide.

Participants will not receive Upadacitinib as part of this study, but will be followed for response to treatment for up to 24 months.

There may be higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits, every 3 months, during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.

Enrollment: 1,532 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of moderate to severe active Rheumatoid Arthritis (RA).
• Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
• Upadacitinib prescribed in accordance to the applicable approved label and local regulatory and reimbursement policies.
• French Participants Only: Taking oral glucocorticoids ≥5 mg/day of prednisone or equivalent for at least 3 months prior to study start.

Exclusion criteria

• Prior treatment with Upadacitinib.

Trial design

1,532 participants in 1 patient group

Participants receiving Upadacitinib

Description:

Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).